Ohio State spinoff raises $59M to tackle deadly disease with no other treatment

Entrada Therapeutics

An Ohio State University spinoff developing a treatment for a deadly mitochondrial disease launched Tuesday in Boston with a $59 million round of venture capital investment.

Entrada Therapeutics is using science developed by Ohio State University professor and company co-founder Dehua Pei to deliver treatment to previously un-druggable targets in the power center of a cell.

Click here to read the complete article, and see related story at WOSU.

Story excerpt provided by Columbus Business First.

Written by Allison DeAngelis.

Originally published December 19, 2018.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: